Full-Time

Associate Director of In Vivo Pharmacology

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior

Middlesex, NJ, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Ph.D. or master’s degree in biological sciences (Immunology, cell biology and cancer biology) or related area
  • Extensive hands-on in vivo study experience (5 years. Expertise in various injection, bleeding, tissue collection and processing).
  • Extensive knowledge and experience in immune cell function analysis and profiling with multi-color flow cytometry, cell coculture and other technologies.
  • Prior experience in CAR-T/NK cell therapy development
  • Three or more year’s leadership experience in an environment of Biotech or pharmaceutical industry
  • Basic toxicology knowledge and experience
  • Strong critical thinking and problem-solving skills
  • Sense of ownership and integrity of their work.
  • A demonstrated ability to work as part of a team
  • Language requirement: Fluent in both English and Mandarin (verbal and written)
Responsibilities
  • Conduct in vivo studies with mice and NHP to assess CAR-T/NK mediated efficacy and toxicity with disease models of tumor or autoimmune disease. This includes designing and implementing in vivo pharmacology studies to support early-stage research programs and late-stage IND-enabling studies
  • Interact with and manage CROs for in vivo study related activities
  • Interact and collaborate with research teams for in vivo pharmacology and toxicology studies
  • Process and analyze tumor and tissues samples from mice and NHP
  • Assess safety and tox risks of cell-based drug products
  • Analyze, document and report all experiment findings
  • Perform additional exploratory and investigational studies with various techniques.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

47%

2 year growth

106%
Simplify Jobs

Simplify's Take

What believers are saying

  • Legend Biotech's recent European Commission approval for CARVYKTI® positions it as a leader in the multiple myeloma treatment market.
  • Strategic partnerships, such as the one with MaxCyte, enhance Legend Biotech's capabilities in cell engineering and expand its technological reach.
  • The company's commitment to transparency and investor relations, demonstrated through regular financial updates, fosters investor confidence and long-term stability.

What critics are saying

  • The competitive landscape in cell therapy and personalized medicine is intense, requiring continuous innovation to maintain market position.
  • Regulatory hurdles and the need for extensive clinical trials can delay the commercialization of new therapies, impacting revenue streams.

What makes Legend Biotech unique

  • Legend Biotech's technology-agnostic approach allows it to explore multiple innovative therapies, unlike competitors who may focus on a single technology.
  • The company's comprehensive business model, from discovery to commercialization, ensures control over the entire treatment lifecycle, providing a competitive edge.
  • Legend Biotech's strong focus on CAR-T therapies, particularly for hematological malignancies and solid tumors, sets it apart in the personalized medicine sector.

Help us improve and share your feedback! Did you find this helpful?